Immune-molecular microenvironment and skin tumors;Microambiente immuno-molecolare e tumori cutanei

Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale

Volumn 54, Issue 3, 2000, Pages 93-108

  De Panfilis, G ^a  

^a SPEDALI CIVILI   (Italy)

Author keywords

Cutaneous microenvironment; Melanoma; Skin immunosurveillance; Tumor immuneprivilege; Tumor skin conflict

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD59 ANTIGEN; CD8 ANTIGEN; COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; DNA; GANGLIOSIDE; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 15; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P53; PROTEIN P56; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VASCULOTROPIN;

DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; REVIEW; SKIN TUMOR; T LYMPHOCYTE;

EID: 0034481384     PISSN: 0365169X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. New perspectives on immunobiology and immunotherapy of melanoma
2. Cell death induced by the Fas/Fas ligand pathway and its role in pathology
3. Involvement of the CD95(Apo1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
4. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
5. Expression of the apoptosis-mediator Fas is enhanced by dysfunctional mitochondria
6. Immunodermatologia e suoi riflessi fisiopatologici "attivi": Le risposte immunitarie cutanee sopraregolatrici
7. T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-zeta complex, recruits intracellular signaling proteins to the plasma membrane
8. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
9. Immunogenetic factors in skin cancer
10. Tumor vaccines
11. Identifying strategies for immune intervention
12. The skin immune system
13. Skin-associated lymphoid tissue (SALT): Origin and functions
14. In situ identification of mononuclear cells infiltrating cutaneous carcinoma: An immuno-histochemical study
15. The role of HLA molecules in the development of skin cancer
16. Density and morphology of Langerhans cells in basal cell carcinomas of the face and trunk
17. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers
18. Dendritic cell activity against primary tumors: An overview
19. Perturbation of epidermal Langerhans cells in basal cell carcinomas
20. Control of Langerhans' cell density by a skin tumour-derived cytokine
21. Carcinogen-induced depletion of cutaneous Langerhans cells
22. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts
23. Tumor antigen presentation of murine epidermal cells
24. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy?
25. Induction of antitumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA
26. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells
27. + T-helper and a T-killer cell
28. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
29. CD8+ cytolytic T lymphocytes and the skin
30. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells
31. Human resting Langerhans cells constitutively bear the Fas-L molecute, but do not express it on the plasma membrane
32. C5A anaphylatoxin and its seven transmembrane-segment receptor
33. Cytolysis of nucleated cells by complement: Cell death displays multi-hit characteristics
34. Distribution of complement regulators (CD46, CD55 and CD59) in skin appendages, and in benignant and malignant skin neoplasms
35. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity
36. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activity in homologous complement-mediated cytotoxicity
37. The vitronectin receptor alpha-V beta-3, contrary to ICAM-1, is not modulated by interferon-gamma and tumour necrosis factor-alpha on melanoma cell lines
38. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
39. Nuclear transport of granzyme B (fragmentin-2): Dependence of perforin in vivo and cytosolic factors in vitro
40. In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains
41. Caspases: Intracellular signaling by proteolysis
42. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively
43. The TNF ligand superfamily and its relevance for human diseases
44. FLICE is activated by association with with the CD95 death-inducing signaling complex (DISC)
45. Analysis of tumor-infiltrating lymphocytes in cutaneous squamous cell carcinoma
46. Human melanoma reactive CD4+ and CD8+CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligandindependent mechanisms for tumor killing
47. Studies of the mechanism of cytolysis by tumourinfiltrating lymphocytes
48. Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes
49. Regression of basal cell carcinoma by intralesional interferonalpha treatments is mediated by CD95(Apo-1/Fas)-CD95 ligand-induced suicide
50. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a bum scar
51. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors
52. Fas and Fas ligand interaction suppress melanoma lung metastasis
53. Regression in basal cell carcinoma: An immunohistochemical analysis
54. Evidence that regression in keratoacanthoma is immunologically mediated: A comparison with squamous cell carcinoma
55. Immunocytochemical analysis of the cellular infiltrate in primary regressing or non-regressing malignant melanoma
56. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas
57. Direct evidence to support the immunosurveillance concept in a human regressive melanoma
58. In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class 1 antigens on tumour cells
59. Is favorable prognosis of squamous cell carcinoma of the skin due to efficient immune surveillance?
60. Immunoelectronmicroscopy detection of Fas-Lexpressing epidemial lymphocytes suspended from normal human skin
61. CD95-lig- and (Fas-L)-expressing epidermal lymphocytes
62. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: Frequency and distribution
63. Tumor antigens recognized by T lymphocytes
64. Serological identification of human tumor antigens
65. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the inmumodominant MART-1/Melan-A antigen
66. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells
67. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
68. Pivotal role of the B7: CD28 pathway in transplantation. Tolerance and tumor immunity
69. Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmunne pigmentation
70. Inflammatory and immunomodulatory roles of TGFbeta
71. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice
72. Maintenance of clonal anergy by endogenously produced IL-10
73. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression
74. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta
75. Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression
76. Inhibitory cytokine circuits involving transforming growth factor-beta, interferon-gamma, and interleukin-2 in human monocyte activation
77. Interleukin-10
78. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells
79. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor infiltrating lymphocytes
80. TGF-beta stimulation and inhibition of cell proliferation: New mechanistic insights
81. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice
82. IL-15: A pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels
83. Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion: Role of different signal peptides
84. Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma
85. The host-tumor immune conflict: From immunosuppression to resistance and destruction
86. Inibition of death receptor signals by cellular FLIP
87. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
88. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
89. Fas ligand is expressed in normal skin and in some cutaneous malignancies
90. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
91. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker
92. Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis
93. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10
94. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells
95. Gene transfer of Fas ligand induces tumor regression in vivo
96. Human melanoma cells do not express Fas(Apo1/CD95) ligand
97. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
98. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases
99. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis
100. Fas ligand in human serum
101. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks this killing
102. Downregulation of Fas ligand by shedding
103. Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody
104. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death
105. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
106. Antitumor effect of locally produced CD95 ligand
107. Fas L: Too much of a good thing?
108. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
109. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study
110. Interleukin-18 and the costimulatory molecule B7-1 have a synergistic antitumor effect on murine melanoma: Implication of combined immunotherapy for poorly immunogenic malignancy
111. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (Apo-1/Fas) receptor/ligand system and involves activation of wild type p53